"10.1371_journal.pone.0118608","plos one","2015-02-27T00:00:00Z","Alan Winston; Rebekah Puls; Stephen J Kerr; Chris Duncombe; Patrick Li; John M Gill; Reshmie Ramautarsing; Simon D Taylor-Robinson; Sean Emery; David A Cooper; for the ALTAIR Study Group","Department of Medicine, Imperial College London, London, United Kingdom; The Kirby Institute, University of New South Wales, Sydney NSW 2052, Australia; HIV NAT, Bangkok, Thailand; Queen Elizabeth Hospital, Hong Kong, Hong Kong; Calgary Health, Alberta, Canada","Conceived and designed the experiments: AW RP SE STR DC. Performed the experiments: AW RP SK CD PL JG RR STR SE DC. Analyzed the data: SK. Wrote the paper: AW RP SK CD PL JG RR STR SE DC.","Alan Winston has received honoraria or research grants, or been a consultant or investigator, in clinical trials sponsored by Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen Cilag, Roche, and Pfizer. John Gill has received honoraria, consultancies and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Bristol-Myers Squibb, Thera, Pfizer, Gilead Sciences, GlaxoSmithKline and Merck Sharp and Dohme. Patrick Li has been an investigator in clinical trials sponsored by Abbott, Bristol-Myers Squibb, Pfizer and Merck Sharp and Dohme, served on advisory boards of Abbott, Pfizer, Janssen-Cilag, Merck Sharp and Dohme, and had been nominated by Queen Elizabeth Hospital and local professional societies to attend conferences through grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, Roche, IDS, Bayer Schering and Merck Serono. David A. Cooper has received honoraria, consultancies and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline and Merck Sharp and Dohme. Sean Emery has received honoraria, consultancies and research grants from (or has been an investigator in clinical trials sponsored by) Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Chiron-Novartis, Gilead Sciences, GlaxoSmithKline, Merck Sharp and Dohme, Roche, Tibotec and Virax Immunotherapeutics. The ALTAIR study was funded with an unrestricted research grant from Gilead Sciences, Foster City, CA, USA. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2015","02","Alan Winston","AW",11,TRUE,5,10,1,10,TRUE,FALSE,TRUE,1,"11",TRUE
